The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Interleukin-6 - A Key Regulator of Colorectal Cancer Development
Open accessAbstract
Growing evidence proposes an important role for pro-inflammatory cytokines during tumor development. Several experimental and clinical studies have linked the pleiotropic cytokine interleukin-6 (IL-6) to the pathogenesis of sporadic and inflammation-associated colorectal cancer (CRC). Increased IL-6 expression has been related to advanced stage of disease and decreased survival in CRC patients. According to experimental studies, these effects are mediated through IL-6 trans-signaling promoting tumor cell proliferation and inhibiting apoptosis through gp130 activation on tumor cells with subsequent signaling through Janus kinases (JAKs) and signal transducer and activator of transcription 3 (STAT3). During recent years, several therapeutics targeting the IL-6/STAT3 pathway have been developed and pose a promising strategy for the treatment of CRC. This review discusses the molecular mechanisms and possible therapeutic targets involved in IL-6 signaling in CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
The risk of colorectal cancer in ulcerative colitis: a meta-analysis
Eaden, J. A., Abrams, K. R., & Mayberry, J. F. (2001) · Gut · doi:10.1136/gut.48.4.526 · Cited by 2,959
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Kishimoto, T. (1989) · Blood · doi:10.1182/blood.v74.1.1.1 · Cited by 2,069
Atreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Self-citationIntestinal Inflammation and Cancer
Ullman, T. A., & Itzkowitz, S. H. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.057 · Cited by 1,119
Bollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, Ö., Schwitalla, S., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.002 · Cited by 946
The two faces of IL-6 on Th1/Th2 differentiation
Diehl, S., & Rincón, M. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00210-9 · Cited by 872
Interleukin 6 and its receptor: ten years later
Hirano, T. (1998) · International Reviews of Immunology · doi:10.3109/08830189809042997 · Cited by 788
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer
Naugler, W. E., & Karin, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.007 · Cited by 730 · cited 1×
“However, monocytes and macrophages seem to be the predominant producers of IL-6 during acute and T cells during chronic inflammation [13].”
BackgroundTGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling
Becker, C., Fantini, M. C., Schramm, C., Lehr, H. A., Wirtz, S., Nikolaev, A., Burg, J., Strand, S., Kiesslich, R., Huber, S., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.020 · Cited by 726
Self-citationTherapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose-John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 683
Interleukin-6 and its receptor: a paradigm for cytokines
Kishimoto, T., Akira, S., & Taga, T. (1992) · Science · doi:10.1126/science.1411569 · Cited by 665
Inflammation as a Tumor Promoter in Cancer Induction
Philip, M., Rowley, D. A., & Schreiber, H. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.06.006 · Cited by 640
Meta‐analysis: colorectal and small bowel cancer risk in patients with Crohn's disease
CANAVAN, C., ABRAMS, K. R., & MAYBERRY, J. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02854.x · Cited by 622
IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer
Neurath, M. F., & Finotto, S. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.02.003 · Cited by 576
Self-citationThe experimental study of tumor progression: a review.
Foulds, L. (1954) · PubMed · Cited by 526
THE PROGRESSION TO CARCINOMA OF VIRUS-INDUCED RABBIT PAPILLOMAS (SHOPE)
Rous, P., & Beard, J. W. (1935) · Journal of Experimental Medicine · doi:10.1084/jem.62.4.523 · Cited by 455
Corvinus, F. M., Orth, C., Moriggl, R., Tsareva, S. A., Wagner, S., Pfitzner, E. B., Baus, D., Kaufman, R., Huber, L. A., Zatloukal, K., et al. (2005) · Neoplasia · doi:10.1593/neo.04571 · Cited by 427
Serum interleukin‐6 levels reflect the disease status of colorectal cancer
Chung, Y., & Chang, Y. (2003) · Journal of Surgical Oncology · doi:10.1002/jso.10269 · Cited by 353
Foulds, L. (1958) · Journal of Chronic Diseases · doi:10.1016/0021-9681(58)90039-0 · Cited by 294
Serum interleukin-6 levels in colorectal cancer patients—a summary of published results
Knüpfer, H., & Preiss, R. (2010) · International Journal of Colorectal Disease · doi:10.1007/s00384-009-0818-8 · Cited by 291
Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.
Sato, K., Tsuchiya, M., Saldanha, J. W., Koishihara, Y., Ohsugi, Y., Kishimoto, T., & Bendig, M. M. (1993) · PubMed · Cited by 274
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
Bataille, R., Barlogie, B., Lu, Z., Rossi, J., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J., & Klein, B. (1995) · Blood · doi:10.1182/blood.v86.2.685.bloodjournal862685 · Cited by 269
Therapeutic Targeting of the Interleukin-6 Receptor
Tanaka, T., Narazaki, M., & Kishimoto, T. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134715 · Cited by 262
Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?
Jarnicki, A., Putoczki, T., & Ernst, M. (2010) · Cell Division · doi:10.1186/1747-1028-5-14 · Cited by 240
The molecular biology of carcinogenesis
Pitot, H. C. (1993) · Cancer · doi:10.1002/1097-0142(19930801)72:3+<962::aid-cncr2820721303>3.0.co;2-h · Cited by 239
Galizia, G., Orditura, M., Romano, C., Lieto, E., Castellano, P., Pelosio, L., Imperatore, V., Catalano, G., Pignatelli, C., & De Vita, F. (2002) · Clinical Immunology · doi:10.1006/clim.2001.5163 · Cited by 227
Eghtedar, A., Verstovsek, S., Estrov, Z., Burger, J., Cortes, J., Bivins, C., Faderl, S., Ferrajoli, A., Borthakur, G., George, S., et al. (2012) · Blood · doi:10.1182/blood-2011-12-400051 · Cited by 200
Belluco, C., Nitti, D., Frantz, M., Toppan, P., Basso, D., Plebani, M., Lise, M., & Jessup, J. M. (2000) · Annals of Surgical Oncology · doi:10.1007/s10434-000-0133-7 · Cited by 196
VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer
Waldner, M. J., Wirtz, S., Jefremow, A., Warntjen, M., Neufert, C., Atreya, R., Becker, C., Weigmann, B., Vieth, M., Rose-John, S., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100438 · Cited by 170
Self-citationRossi, J.-F., Négrier, S., James, N. D., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P., & Berns, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605872 · Cited by 166
Rigby, R. J., Simmons, J. G., Greenhalgh, C. J., Alexander, W. S., & Lund, P. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210286 · Cited by 154
Grivennikov, S. I., Karin, E., Terzić, J., Mucida, D., Yu, G., Vallabhapurapu, S., Scheller, J., Rose‐John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.003 · Cited by 142
Interleukin-6 gene amplification and shortened survival in glioblastoma patients
Tchirkov, A., Khalil, T. A., Chautard, E., Mokhtari, K., Véronèse, L., Irthum, B., Vago, P., Kemeny, J., & Verrelle, P. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603586 · Cited by 140
Karkera, J. D., Steiner, H., Li, W., Skradski, V., Moser, P. L., Riethdorf, S., Reddy, M. P., Puchalski, T. A., Safer, K., Prabhakar, U., et al. (2011) · The Prostate · doi:10.1002/pros.21362 · Cited by 116
Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer
Guo, Y., Nemeth, J. A., O'Brien, C. W., Susa, M., Liu, X., Zhang, Z., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1095 · Cited by 106
New therapeutic strategies for treatment of inflammatory bowel disease
Atreya, R. N., & Neurath, M. F. (2008) · Mucosal Immunology · doi:10.1038/mi.2008.7 · Cited by 84
Self-citationHitting a complex target: an update on interleukin-6 trans-signalling
Waetzig, G. H., & Rose‐John, S. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.660307 · Cited by 83
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL–6 trans-signaling
Becker, C., Fantini, M. C., Schramm, C., Lehr, H., Wirtz, S. J., Becker, A., Burg, J., Strand, S., Kießlich, R., Huber, S., et al. (2004) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2004-831593 · Cited by 67
Self-citationInterleukin‐6 Levels in Colorectal Cancer Tissues
Komoda, H., Tanaka, Y., HONDA, M., Matsuo, Y., Hazama, K., & Takao, T. (1998) · World Journal of Surgery · doi:10.1007/s002689900489 · Cited by 63
Lahm, H., Petral-Malec, D., Yilmaz, A., Fischer, J. R., Lorenzoni, M., Givel, J., & Odartchenko, N. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90031-v · Cited by 59
Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6
Legouffe, É., Liautard, J., GAILLARD, J. P., Rossi, J.-F., Wijdenes, J., Bataille, R., Klein, B., & Brochier, J. (1994) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1994.tb06145.x · Cited by 54
Seavey, M. M., Lu, L. D., Stump, K. L., Wallace, N. H., Hockeimer, W., O’Kane, T. M., Ruggeri, B., & Dobrzański, P. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0951 · Cited by 42
Therapeutic Blockade of Interleukin-6 in Chronic Inflammatory Disease
Yamamoto, K., & Rose‐John, S. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.11 · Cited by 36
Cited by
Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000
Role of interleukin-6 in cancer progression and therapeutic resistance
Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5098-7 · Cited by 1,092
Wu, X., Tao, P., Zhou, Q., Li, J., Yu, Z., Wang, X., Li, J., Li, C., Yan, M., Zhu, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15119 · Cited by 367
Tabernero, J., Lenz, H.-J., Siena, S., Sobrero, A., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00138-2 · Cited by 328
Masjedi, A., Hashemi, V., Hojjat-Farsangi, M., Ghalamfarsa, G., Azizi, G., Yousefi, M., & Jadidi-Niaragh, F. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.177 · Cited by 303
Metadata
- Authors
- Waldner, M. J., Foersch, S., & Neurath, M. F.
- Venue
- International Journal of Biological Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2012
- Volume
- 8
- Issue
- 9
- Pages
- 1248-1253
- ISSN
- 1449-2288 (ISSN-L)
- OpenAlex
- W2102154168
- Cited by
- 418
- References
- 46
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.